PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has broadened its collaboration with Moderna, Inc. (Nasdaq: MRNA) to focus on developing treatments for autoimmune diseases, marking a significant step in leveraging Carisma’s chimeric antigen receptor macrophage (CAR-M) technology. This expanded partnership involves the nomination of two specific targets for these diseases, with Carisma holding rights to other autoimmune targets outside this agreement.
The collaboration will harness Carisma’s proprietary CAR-M platform alongside Moderna’s mRNA/LNP technology to innovate in vivo macrophage engineering approaches. Under this agreement, Carisma will manage the discovery and optimization of development candidates, while Moderna will oversee clinical development and potential commercialization. Carisma will benefit from research funding and is in line to receive milestone payments and royalties on net sales from any developed products.
Steven Kelly, CEO of Carisma, stated, “The nomination of the two autoimmune targets is a significant milestone in our mission to harness the power of macrophages to treat a broader range of diseases.” Lin Guey, PhD, CSO of Therapeutic Research Ventures at Moderna, added, “We continue to believe that the combination of our platform and Carisma’s deep myeloid biology expertise could lead to innovative treatments for patients.”
This partnership expansion highlights the potential for innovative therapies in treating autoimmune conditions, utilizing cutting-edge CAR-M technology and mRNA advancements.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.